Oral administration of collagen conjugated with cholera toxin induces tolerance to type II collagen and suppresses chondritis in an animal model of autoimmune ear disease

被引:20
作者
Kim, N
Cheng, KC
Kwon, SS
Mora, R
Barbieri, M
Yoo, TJ
机构
[1] Univ Tennessee, Sch Med, Div Allergy & Immunol, Dept Med, Memphis, TN 38163 USA
[2] Vet Adm Med Ctr, Res Serv, Memphis, TN 38104 USA
[3] Korea Adv Inst Sci & Technol, Ctr Biomed Res, Taejon 305701, South Korea
[4] Univ Genoa, Dept Otolaryngol, Genoa, Italy
关键词
cholera toxin B subunit; chondritis; oral tolerance; type II collagen;
D O I
10.1177/000348940111000710
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
B10.RIII (H-2(r)) mice were orally administered cyanogen bromide peptide 11 (CB11) or cholera toxin B (CTB)-conjugated CB 11 to induce tolerance in collagen-induced autoimmune ear disease. Oral administration of a high dosage of CB Il provided partial protection from chondritis. However. administration of a tiny amount of CTB-CB 11 conjugate effectively suppressed chondritis. Oral administration of CTB-CB 11 conjugate did not alter the stimulation of T cells in vitro or the fine specificities of B cells. The oral administration of CTB-CB 11 caused a higher level of type II collagen-specific IgG and its subclass. Interestingly, increases of TH 1 cytokine (interferon-gamma) in Peyer's patches and of TH1/TH2 cytokines (interleukin-2 and interleukin-4) in lymph nodes were detected in mice that had been fed CTB-CB 11. An increase of CD8(+) T cells in the Peyer's patches with a decrease of CD8(+) T cells in lymph nodes was seen in mice that had been fed CTB-CB Il. These results suggest that protection from chondritis by oral administration of minute amounts of CTB-CB 1 1 conjugate can be achieved by a mechanism distinct from that of conventional oral tolerance induction.
引用
收藏
页码:646 / 654
页数:9
相关论文
共 50 条
[1]   A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes [J].
Bergerot, I ;
Ploix, C ;
Petersen, J ;
Moulin, V ;
Rask, C ;
Fabien, N ;
Lindblad, M ;
Mayer, A ;
Czerkinsky, C ;
Holmgren, J ;
Thivolet, C .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (09) :4610-4614
[2]   SUPPRESSION OF EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS BY THE ORAL-ADMINISTRATION OF MYELIN BASIC-PROTEIN [J].
BITAR, DM ;
WHITACRE, CC .
CELLULAR IMMUNOLOGY, 1988, 112 (02) :364-370
[3]  
BRAND DD, 1994, J IMMUNOL, V152, P3088
[4]   SUPPRESSION OF EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS BY ORAL-ADMINISTRATION OF MYELIN ANTIGENS .4. SUPPRESSION OF CHRONIC RELAPSING DISEASE IN THE LEWIS RAT AND STRAIN-13 GUINEA-PIG [J].
BROD, SA ;
ALSABBAGH, A ;
SOBEL, RA ;
HAFLER, DA ;
WEINER, HL .
ANNALS OF NEUROLOGY, 1991, 29 (06) :615-622
[5]   PROTEIN THIOLATION AND REVERSIBLE PROTEIN-PROTEIN CONJUGATION - N-SUCCINIMIDYL 3-(2-PYRIDYLDITHIO)PROPIONATE, A NEW HETEROBIFUNCTIONAL REAGENT [J].
CARLSSON, J ;
DREVIN, H ;
AXEN, R .
BIOCHEMICAL JOURNAL, 1978, 173 (03) :723-737
[6]   AURICULAR CHONDRITIS IN RATS - AN EXPERIMENTAL-MODEL OF RELAPSING POLYCHONDRITIS INDUCED WITH TYPE-II COLLAGEN [J].
CREMER, MA ;
PITCOCK, JA ;
STUART, JM ;
KANG, AH ;
TOWNES, AS .
JOURNAL OF EXPERIMENTAL MEDICINE, 1981, 154 (02) :535-540
[7]   Cholera toxin B subunit as transmucosal carrier-delivery and immunomodulating system for induction of antiinfectious and antipathological immunity [J].
Czerkinsky, C ;
Sun, JB ;
Lebens, M ;
Li, BL ;
Rask, C ;
Lindblad, M ;
Holmgren, J .
ORAL TOLERANCE: MECHANISMS AND APPLICATIONS, 1996, 778 :185-193
[8]  
ELSON CO, 1995, J IMMUNOL, V154, P1032
[9]   INDUCTION OF ANERGY OR ACTIVE SUPPRESSION FOLLOWING ORAL TOLERANCE IS DETERMINED BY ANTIGEN DOSAGE [J].
FRIEDMAN, A ;
WEINER, HL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (14) :6688-6692
[10]   Molecular basis of type II collagen autoimmune disease: Observations of arthritis, auricular chondritis and tympanitis in mice [J].
Fujiyoshi, T ;
Cheng, KC ;
Krug, MS ;
Yoo, TJ .
ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY AND ITS RELATED SPECIALTIES, 1997, 59 (04) :215-229